Cold! Three studies of NEJM/Nature have proved that chloroquine is untreatable in the treatment of COVID-19/SARS-CoV-2!

!--webeditor:page title"--July 27, 2020 / COVID-19 has quickly become a pandemic, and there are no antiviral drugs or vaccines available. several clinical studies are under wayto assess the efficacy of drugs that have been shown to have antiviral efficacy in vitro.of these candidate drugs, chloroquine and hydroxychloroquine (HCQ) were highly regarded in the early stages of the outbreak, particularly by U.S. President Donald Trump, which has led to their use in thousands of people worldwide, but there is growing evidence that chloroquine and hydroxychloroquine simply do not prevent SARS-CoV-2 infection or treat COVID-19.recently, three preclinical and clinical studies published in Nature and New England Journal of Medicine have once again proved that these two drugs are ineffective! Researchers from the University of Paris-Saclay and other units assessed the antiviral activity of HCQ in vitro and in macaques infected with SARS-CoV-2.HCQ showed antiviral activity in African green monkey kidney cells (VeroE6), but did not show results in reconstructed epidermal models.related research published in Nature (Hydroxyyyquine use against SARS-CoV-2 infection in non-human primates).researchers tested different treatment strategies in macaques, including individual or combined azithromycin (AZTH) before and after the peak of viral load.results showed that neither HCQ nor HCQ-AZTH had a significant impact on the viral load levels in any test chamber.HCQ does not provide protection against infection when the drug is used as pre-exposure prophylaxis (PrEP).the results of this study do not support the use of HCQ -- either alone or in combination with AZTH -- as an antiviral treatment for human COVID-19.photo source: chloroquine is an antimalarial drug that was previously used in COVID-19 treatment because studies have shown that it inhibits the spread of SARS-CoV-2 in the kidney-derived cell line Vero.in another study published in Nature (chloroquine no inhibit no- human lung cells with SARS-CoV-2), researchers from the Leibniz Primate Institute and other units demonstrated that the engineering expression of TMPRSS2 -- the cell protease that activates SARS-CoV-2 into lung cells -- makes Vero cells infected with SARS-CoV-2 insensitive to chlorpyrifos., the researchers demonstrated that chloroquine does not block THE SARS-CoV-2 infection of the TMPRS2-positive lung cell line Calu-3.these results show that chloroquine is targeted at a viral activation pathway that does not work in lung cells and is unlikely to prevent the spread of SARS-CoV-2 in and between patients.in a separate study published in the New England Journal of Medicine (Hydroxyyquine with or without Azithromycin in Mild-to-Moderate Covid-19), researchers from the HCor Institute in Brazil conducted a three-group control trial involving suspected or confirmed COVID-19 hospitalizations, who either did not receive supplementary oxygen or received up to 4 litres of oxygen per minute.patients were randomly assigned to three groups, respectively, to receive standard treatment, standard treatment of 400 mg of hydroxychloroquine treatment twice a day, or standard treatment, two daily 400 mg of hydroxychloroquine therapy, and one daily 500 mg of azithromycin treatment, for 7 days. the main outcome ofwas the use of a seven-level sequential scale (1-7, the worse the disease) was used to assess the clinical status of the improved intentional treatment population (COVID-19 diagnosed patients) over a 15-day period. in the study, 667 patients were randomly grouped, and 504 patients were diagnosed with COVID-19, incorporating improved intentional therapy analysis. compared to standard treatment, the use of hydroxychloroquine or hydroxychloroquine-azithromycin treatment only had no effect on the ratio of a higher score of seven-stage sequence scale on the 15th day (the advantage ratio was 1.21, 95% confidence interval of 0.69 to 2.11, P . . . 1.00 or the advantage ratio was 0.99, 95% CI was 0.57 to 1.73, P . patients treated only with hydroxychloroquine or azithromycin had an increasein lyse-in-correction between QTs and elevated liver enzyme levels compared to patients who were not treated with any of the drugs. therefore, the researchers concluded that the use of hydroxychloroquine or azithromycin did not improve the clinical condition of patients on the 15th day compared to standard treatment in patients with mild to moderate COVID-19 hospitalizations. () References: Maisonnase, P., Guedj, J., Contreras, V. et al. Hydroxyychloroquine use against SARS-CoV-2 infection in non-human primates. Nature (2020). https://doi.org/10.1038/s41586-020-2558-4Hoffmann, M., M? Sbauer, K., Hofmann-Winkler, H. et Al. Chloro. No. No ar or san slung with SARS-CoV-2. Nature (2020). https://doi.org/10.1038/s41586-020-2575-3-!--/ewebeditor:page-!---ewebeditor:page title"--Alexandre B. Cavalcanti et al. Hydroysyqueyquine with or Witho azithromycin in-to-moderate-moderate-co-s19. NEJM. 2020. DOI: 10.1056/NEJMoa2019014 !--/ewebeditor: page.